Completed OBSERVATIONAL NCT03466775

Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes

Sponsor: Center for Cardiovascular Research Berlin

Conditions Kidney Transplant Failure and Rejection

Interventions Allograft rejection appearance Allograft survival Anti-angiotensin II type 1 receptor antibody measurement Measurement of ENDAT expression level allograft

Updated 5 times since 2018 Last updated: Mar 9, 2018 Started: Jan 1, 2008 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03466775, this observational or N/A phase trial focuses on Kidney Transplant Failure and Rejection and remains completed. Sponsored by Center for Cardiovascular Research Berlin, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Center for Cardiovascular Research Berlin
Paris Translational Research Center for Organ Transplantation

Data source: Paris Translational Research Center for Organ Transplantation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France